源自枯草芽孢杆菌的微生物多肽在制备抗肿瘤疫苗中的应用
By cross-reacting the microbial polypeptide YSDELFVEL derived from Bacillus subtilis with the tumor antigen FINDEIFVEL overexpressed by EZH2, an anti-tumor vaccine was prepared, solving the problem of immune tolerance in TAA vaccines and achieving highly effective tumor treatment and prevention.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HARBIN MEDICAL UNIVERSITY
- Filing Date
- 2026-03-27
- Publication Date
- 2026-07-17
AI Technical Summary
Existing tumor vaccines, especially TAA vaccines, suffer from immune tolerance issues, making it difficult to effectively activate the immune system to attack tumor cells. Furthermore, their production costs are high, hindering large-scale deployment.
Using the microbial polypeptide YSDELFVEL derived from Bacillus subtilis, which has high homology with FINDEIFVEL, a tumor-associated antigen overexpressing EZH2, an anti-tumor vaccine was prepared by activating T cells through cross-reaction, which is suitable for tumor types overexpressing EZH2.
It significantly improves T-cell activation efficiency, effectively kills tumor cells, reduces preparation costs, facilitates large-scale production, and has dual potential for tumor treatment and prevention, making it suitable for a variety of common cancers.
Smart Images
Figure CN121944092B_ABST
Abstract
Citation Information
Patent Citations
Bacillus marinus S-1 and anti-tumor active polypeptide produced thereby
CN103555622A
Immunogenic peptides for the treatment of prostate and breast cancer
US20060140967A1